News brief­ing: Five Prime fi­nal­izes PhI­II plans for gas­tric can­cer; AI di­ag­nos­tics-fo­cused Paige ex­pands staff

Five Prime Ther­a­peu­tics has fi­nal­ized a plan to take their come­back gas­tric can­cer drug in­to late-stage stud­ies.

The South San Fran­cis­co-based biotech re­leased full Phase II da­ta for be­mar­ituzum­ab on Fri­day, which Five Prime said in No­vem­ber met all of its pre-spec­i­fied ef­fi­ca­cy end­points in a topline read­out. Now, the com­pa­ny is an­nounc­ing it plans to launch a Phase III tri­al for the pro­gram in 2021. Fol­low­ing No­vem­ber’s read­out, the fu­ture of be­mar­ituzum­ab had not yet been fi­nal­ized.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER